Literature DB >> 28419437

A New Paradigm. "Learn - Learn More"; Dose-Exposure-Response at the Center of Drug Development and Regulatory Approval.

Alan Maloney1.   

Abstract

In his seminal paper, Lewis Sheiner introduced the "Learning versus Confirming" paradigm. From that foundation, this work proposes why the precise estimation of the dose-exposure-response (D-E-R) for both efficacy and safety endpoints should be the ultimate goal for most drug development programs. The subsequent identification and approval of an optimal dose regimen range will provide a pragmatic framework for delivering personalized medicine based on dose titration for each and every patient.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2017        PMID: 28419437     DOI: 10.1002/cpt.710

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Body of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016.

Authors:  Asbjørn Nøhr-Nielsen; Marie Louise De Bruin; Mikael Thomsen; Christian Bressen Pipper; Theis Lange; Ole Jannik Bjerrum; Trine Meldgaard Lund
Journal:  Br J Clin Pharmacol       Date:  2019-06-17       Impact factor: 4.335

Review 2.  Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.

Authors:  René J Boosman; Jacobus A Burgers; Egbert F Smit; Neeltje Steeghs; Anthonie J van der Wekken; Jos H Beijnen; Alwin D R Huitema; Rob Ter Heine
Journal:  Drugs       Date:  2021-12-11       Impact factor: 9.546

3.  A Systematic Assessment of US Food and Drug Administration Dosing Recommendations For Drug Development Programs Amenable to Response-Guided Titration.

Authors:  Lingshan Wang; Kimberly Maxfield; Daphne Guinn; Rajanikanth Madabushi; Issam Zineh; Robert N Schuck
Journal:  Clin Pharmacol Ther       Date:  2020-11-15       Impact factor: 6.903

Review 4.  Precision Dosing: An Industry Perspective.

Authors:  Richard W Peck
Journal:  Clin Pharmacol Ther       Date:  2020-10-26       Impact factor: 6.903

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.